EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Regulatory · The food–drug gap Statute and regulation Primary sources checked October 28, 2026

The food–drug gap

U.S. law sorts a plant product by the claim made for it, not by how long people have used it, and a treatment claim makes it a drug. Few botanicals cross that line because the proof is costly, cannot be owned, and is hard to reproduce batch to batch.

4botanical products approved by FDA as prescription drugs (NDA or BLA)
739botanical investigational new drug applications received by FDA, March 1984 to December 2020
5 vs 0years of new chemical entity exclusivity for an approved drug, against none for a supplement
30 yearsof medicinal use, 15 of them in the EU, for an EU traditional herbal registration

Not legal advice. This page explains published law and data as of October 28, 2026. EUTECNIQ Sciences is a company in formation: no laboratory, products, studies or claims exist, and everything about EUTECNIQ below is proposed.

Start here if new to the topic: Course 10, Supplements and disease claims covers DSHEA, the ten disease-claim criteria of 21 CFR 101.93(g), FTC substantiation and a sorter of FDA's own examples. This page goes one level down: why the gap exists and what can legitimately be done about it.

The legal mechanism

Intended use sets the category

A drug is any article “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease” (FD&C Act § 201(g)(1)(B)). Origin does not enter the test. Psyllium husk shows it: it is sold as a supplement ingredient, it carries an authorized health claim, and it can be sold under an over-the-counter drug monograph, depending on what the label says the product is for. Between “supports normal function” and “treats” there are two rungs, both about reducing disease risk, and each needs more evidence than the one below.

Four rungs of U.S. claims; only the top rung may say “treats”, and it turns the product into a drugStatute and regulation Schematic
The US claim ladder: structure/function statements, qualified health claims, authorized health claims and drug claims, with the evidence each needs and a botanical example on each rungEvidence and FDA review required rise from left to rightStructure/function statementStructure/function statementEffect on normal structure orfunction of the bodyNo FDA review before sale. FDAnotified within 30 days ofmarketing; label disclaimer; firmholds substantiation.21 USC 343(r)(6); 21 CFR 101.93Qualified health claimQualified health claimReduced risk of a disease, withqualifying languageEvidence below significantscientific agreement. FDA petition;letter of enforcement discretion.Cranberry products and recurrenturinary tract infection in healthywomen (2020); psyllium husk andtype 2 diabetes (2014)Authorized health claimAuthorized health claimReduced risk of a diseaseSignificant scientific agreementamong qualified experts (21 CFR101.14(c)); FDA regulation.Psyllium husk and heart disease, 21CFR 101.81: 7 g soluble fiber perday, at least 1.7 g per servingDrug claimDrug claimDiagnose, cure, mitigate, treat orprevent a diseaseProduct becomes a drug (21 USC321(g)(1)(B)). Clinical trials underan IND; NDA or BLA approval.Four botanical drugs approved:sinecatechins 2006, crofelemer2012, anacaulase-bcdb 2022, birchtriterpenes 2023Supplement law: claims up to here, never disease treatmentDrug lawThe US claim ladder from drug claims down to structure/function statementsFrom the top rung down: less evidence, nodisease-treatment claimDrug claimDiagnose, cure, mitigate, treat or prevent adisease. Product becomes a drug (21 USC321(g)(1)(B)). Clinical trials under an IND; NDA orBLA approval.Example: Four botanical drugs approved:sinecatechins 2006, crofelemer 2012,anacaulase-bcdb 2022, birch triterpenes 2023Above: drug law. Below: supplement lawAuthorized health claimReduced risk of a disease. Significant scientificagreement among qualified experts (21 CFR101.14(c)); FDA regulation.Example: Psyllium husk and heart disease, 21 CFR101.81: 7 g soluble fiber per day, at least 1.7 g perservingQualified health claimReduced risk of a disease, with qualifyinglanguage. Evidence below significant scientificagreement. FDA petition; letter of enforcementdiscretion.Example: Cranberry products and recurrent urinarytract infection in healthy women (2020); psylliumhusk and type 2 diabetes (2014)Structure/function statementEffect on normal structure or function of the body.No FDA review before sale. FDA notified within 30days of marketing; label disclaimer; firm holdssubstantiation.Example: 21 USC 343(r)(6); 21 CFR 101.93
21 USC 321(g)(1) and 343(r)(6); 21 CFR 101.14(c), 101.81 and 101.93; FDA, Qualified Health Claims: Letters of Enforcement Discretion; FDA CDER, What is a Botanical Drug? (updated September 3, 2026).
The four rungs, with the botanical example on each
RungMay sayWhat it needsBotanical example
Structure/function statementHow an ingredient affects the normal structure or function of the body; may not claim to diagnose, mitigate, treat, cure or prevent a diseaseNotice to FDA no later than 30 days after first marketing; the label disclaimer “This statement has not been evaluated by the Food and Drug Administration…”; substantiation held by the firmAny supplement label; FDA does not review the statement before sale
Qualified health claimA relationship between a substance and reduced risk of a disease, with qualifying language on the strength of evidencePetition; FDA letter of enforcement discretionCranberry products and reduced risk of recurrent urinary tract infection in healthy women (letter of July 21, 2020); psyllium husk and type 2 diabetes (June 24, 2014)
Authorized health claimA relationship between a substance and reduced risk of a disease“Significant scientific agreement, among experts qualified by scientific training and experience” (21 CFR 101.14(c)); an FDA regulationPsyllium husk and heart disease (21 CFR 101.81): 7 g or more of soluble fiber from psyllium seed husk per day, at least 1.7 g per serving
Drug claimDiagnoses, cures, mitigates, treats or prevents a diseaseClinical investigation under an IND and approval of an NDA or BLAFour approvals: sinecatechins (Veregen, 2006), crofelemer (Fulyzaq, also Mytesi, 2012), anacaulase-bcdb (NexoBrid, BLA, 2022), birch triterpenes (Filsuvez, 2023)

Sources: 21 USC 321 and 343 (LII, read October 28, 2026); eCFR 21 CFR 101.14, 101.81, 101.93 (current to October 2026); FDA qualified health claims list; FDA CDER botanical drug page; approval years from Park et al., Ther Innov Regul Sci 2025. Psyllium and witch hazel can also be sold under certain over-the-counter drug monographs (FDA CDER).

Root cause 1 · Economics

Proof that nobody can own

A product of nature is not patent-eligible merely because it was isolated (Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576, 2013), and natural laws are not patentable (Mayo v. Prometheus, 566 U.S. 66, 2012). A firm can patent a composition, a process, a formulation or a method of use, but not the plant or its known constituent. Drugs add statutory exclusivity on top of patents; supplements get none. A trial on a widely sold extract therefore helps every seller of that extract, and the firm that paid for it cannot stop them.

An approved drug carries years of statutory exclusivity; a supplement backed by the same trial carries noneStatute
Years of market exclusivity attached by statute: orphan drug 7, new chemical entity 5, new clinical investigation 3, pediatric 0.5 added to existing protection, dietary supplement 0Years of exclusivity from FDA lawOrphan drug exclusivityOrphan drug exclusivity: 7 years7 yrNew chemical entity exclusivityNew chemical entity exclusivity: 5 years5 yrNew clinical investigation exclusivityNew clinical investigation exclusivity: 3 years3 yrPediatric exclusivity (added on)Pediatric exclusivity (added on): 0.5 years0.5 yrDietary supplement: any statutory dataexclusivityDietary supplement: any statutory data exclusivity: 0 yearsnoneApproved drugs only; patents are separate and granted by the USPTO.Years of market exclusivity attached by statute: orphan drug 7, new chemical entity 5, new clinical investigation 3, pediatric 0.5 added to existing protection, dietary supplement 0Years of exclusivity from FDA lawOrphan drug exclusivityOrphan drug exclusivity: 7 years7 yrNew chemical entityexclusivityNew chemical entity exclusivity: 5 years5 yrNew clinicalinvestigation exclusivityNew clinical investigation exclusivity: 3 years3 yrPediatric exclusivity(added on)Pediatric exclusivity (added on): 0.5 years0.5 yrDietary supplement: anystatutory dataexclusivityDietary supplement: any statutory data exclusivity: 0 yearsnoneApproved drugs only; patents are separate and grantedby the USPTO.
FDA, Frequently Asked Questions on Patents and Exclusivity (read October 28, 2026). Exclusivity attaches on approval of a drug product when statutory requirements are met; pediatric exclusivity adds six months to existing patents or exclusivity.
What protects the firm that pays for the evidence
ProtectionApproved botanical drugBotanical supplement
Patent on the plant or a known constituent as suchNo (Myriad 2013; Mayo 2012)No
Patent on a composition, process, formulation or method of useAvailableAvailable
New chemical entity exclusivity5 years, if the active ingredient qualifiesNone
New clinical investigation exclusivity3 yearsNone
Orphan drug exclusivity7 yearsNone
Claim the trial earnsThe approved indicationAt most a health claim on risk reduction; never treatment

The record shows the result. When the HHS Office of Inspector General collected the substantiation that 66 of 104 manufacturers sent for their structure/function claims, “only 2 percent of the 557 human studies” examined the actual products sampled, and 85 percent were not randomized, double-blind, parallel-group and placebo-controlled.

Sources: 569 U.S. 576 (2013); 566 U.S. 66 (2012); FDA patents and exclusivity FAQ; HHS OIG, Dietary Supplements: Structure/Function Claims Fail To Meet Federal Requirements, OEI-01-11-00210, October 2012, pp. 11–13. Whether a given ingredient qualifies for any exclusivity is a case-specific legal question.

Root cause 2 · Preclusion

The first-lawful-use race

The supplement definition excludes an article approved as a new drug, or authorized for investigation as one where “substantial clinical investigations have been instituted” and made public, if it “was not before such approval, certification, licensing, or authorization marketed as a dietary supplement or as a food” (21 USC 321(ff)(3)(B)). Order decides the channel. A firm that runs a public drug program first can close the supplement market for that article; a firm that sells first keeps it open for everyone.

The same article, two orders of events, two outcomesStatute Schematic
Two orders of events: supplement or food marketing first keeps both channels; a public drug investigation or approval first excludes the article from the supplement definitionTime order of eventsOutcomeSupplement or foodfirstMarketed as a dietarysupplement or foodBefore any drug approval or publicinvestigationLater: IND or drug approvalClinical program on the same articleBoth channels can existThe exclusion in 321(ff)(3)(B) does notapplyDrug investigationfirstApproved as a drug, orsubstantial clinical investigationsinstituted and made publicUnder an INDLater: sold as a supplementArticle not marketed as a supplementor food beforeExcluded from the supplementdefinitionUnless FDA issues a regulation. FDAapplied this to CBD (Epidiolex)Order of first lawful use and its outcomeSupplement or food firstMarketed as a dietary supplement or foodBefore any drug approval or public investigationLater: IND or drug approvalClinical program on the same articleBoth channels can existThe exclusion in 321(ff)(3)(B) does not applyDrug investigation firstApproved as a drug, or substantial clinicalinvestigations instituted and made publicUnder an INDLater: sold as a supplementArticle not marketed as a supplement or foodbeforeExcluded from the supplement definitionUnless FDA issues a regulation. FDA applied this toCBD (Epidiolex)
21 USC 321(ff)(3)(B) (LII); FDA, Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD), content current as of July 16, 2024.
How FDA applied the exclusion to a plant-derived substance
Question in § 201(ff)(3)(B)FDA's answer for CBD
Is it the active ingredient in an approved drug?Yes: “CBD is the active ingredient in the approved drug product, Epidiolex.”
Were substantial clinical investigations instituted and made public?Yes, FDA states they were
Was it marketed as a supplement or food first?Not the case, based on the evidence available to FDA
Can FDA lift the exclusion?Only by notice-and-comment regulation; FDA states it has issued none for any substance

Source: FDA cannabis and CBD page (read October 28, 2026). The same page reaches the same conclusion for THC (Marinol, Syndros).

Root cause 3 · Chemistry

Why botanical drug programs stall

A botanical drug is a mixture whose composition moves with species, cultivar, soil, harvest and extraction. FDA authors reviewing 739 botanical INDs report that standard chemistry, manufacturing and controls “alone sometimes are not sufficient”; early programs were held or withdrawn for “insufficient information on botanical raw materials”, and late-phase trials met the hurdle of “the rigorous evidence-based requirements necessary for drug approval”. FDA's 2016 Botanical Drug Development guidance answers with a “totality of the evidence” approach to batch consistency.

Hundreds of botanical INDs, four approvals: the bar for the approvals is barely visible at this scaleFDA data
Botanical INDs at FDA, March 1984 to December 2020: 739 received, 485 non-oncology and 254 oncology, 253 active in December 2020, 6 oncology INDs proposing phase 3, against 4 botanical drugs approvedNumber of applicationsBotanical INDs received, March 1984 to December 2020Botanical INDs received, March 1984 to December 2020: 739739Non-oncology INDsNon-oncology INDs: 485485Oncology INDsOncology INDs: 254254Active in December 2020 (82 oncology, 171 other)Active in December 2020 (82 oncology, 171 other): 253253Oncology INDs proposing phase 3Oncology INDs proposing phase 3: 66Botanical NDAs and BLAs approved, 2006 to 2023Botanical NDAs and BLAs approved, 2006 to 2023: 44IND counts from FDA authors (2025); approvals from FDA CDER. All four approvals are for non-oncology indications.Botanical INDs at FDA, March 1984 to December 2020: 739 received, 485 non-oncology and 254 oncology, 253 active in December 2020, 6 oncology INDs proposing phase 3, against 4 botanical drugs approvedNumber of applicationsBotanical INDs received,March 1984 toDecember 2020Botanical INDs received, March 1984 to December 2020: 739739Non-oncology INDsNon-oncology INDs: 485485Oncology INDsOncology INDs: 254254Active in December2020 (82 oncology, 171other)Active in December 2020 (82 oncology, 171 other): 253253Oncology INDsproposing phase 3Oncology INDs proposing phase 3: 66Botanical NDAs andBLAs approved, 2006 to2023Botanical NDAs and BLAs approved, 2006 to 2023: 44IND counts from FDA authors (2025); approvals fromFDA CDER. All four approvals are for non-oncologyindications.
IND counts end in December 2020; the approval count runs to 2023. Other FDA counts (“over 400” since 2004; more than 600 pre-INDs and INDs) use different definitions and dates.Park JK, Lee D, Rui L, Gao X, Furness MS, Wu C. Ther Innov Regul Sci 2025;59:1129–1137, doi:10.1007/s43441-025-00786-y; FDA CDER, What is a Botanical Drug?
Three kinds of evidence, viewed together, show that marketed batches match the batches tested in trialsFDA guidance
Three kinds of evidence viewed together support the therapeutic consistency of marketed batches with clinical batchesRaw material controlBotanical raw material: agricultural andcollection practicesChemistry and manufacturing controlChemical quality control and processcontrols, including validationBiological assay and clinical dataAssay reflecting the known or intendedmechanism; clinical data across severalbatchesTherapeutic consistencyMarketed batches remain therapeutically consistent with the batches used in theclinical trialsThree kinds of evidence support therapeutic consistencyRaw material controlBotanical raw material: agricultural and collectionpracticesChemistry and manufacturing controlChemical quality control and process controls,including validationBiological assay and clinical dataAssay reflecting the known or intendedmechanism; clinical data across several batchesTherapeutic consistencyMarketed batches consistent with clinical batches
FDA, Botanical Drug Development: Guidance for Industry, December 2016, Sections III.B and VII.F; Section VI.F.1 “highly recommended” randomizing subjects to different batches at each site.
The four botanical products FDA has approved as prescription drugs
ProductActive ingredientApplicationApproved
VeregenSinecatechinsNDA2006
Fulyzaq (also Mytesi)CrofelemerNDA2012
NexoBridAnacaulase-bcdbBLA2022
FilsuvezBirch triterpenesNDA2023

Sources: FDA CDER, What is a Botanical Drug? (updated September 3, 2026); years from Park et al. 2025. None of the four is for an oncology indication.

Evidence

Traditional use is exposure, not proof

Centuries of use show that people took a preparation and that acute, obvious harm was not noticed. They cannot show which species and dose were used, whether the effect beat placebo, or whether slow harms such as cancer or kidney failure occurred. Both histories below began in classical texts; one ended in a Nobel Prize, the other in an IARC Group 1 listing.

The same kind of source, two outcomes: tested chemistry made one a medicine, and testing exposed the other as a carcinogenPrimary records
Artemisinin, from a classical prescription text to a 2015 Nobel Prize, beside aristolochic acid, from substituted slimming pills to IARC Group 1 and an FDA import alertA lead that became a medicine: artemisininTextGe Hong's Handbookof Prescriptions forEmergencies: qinghaosteeped in cold water,juice drunk1969Over 2,000prescriptionsgathered, 640shortlistedOct 4, 1971Sample 191, neutralether extract made atlow temperature:100% effective inrodent malaria1972First patients, Aug toOct; artemisininisolated in November1986Artemisinin New DrugCertificate, China2015Nobel Prize inPhysiology orMedicine, one half toTu YouyouA traditional ingredient that caused harm: aristolochic acidBelgiumAristolochia fangchi replacedStephania tetrandra in Belgianslimming pillsNEJM, 200018 of 39 patients with end-stagenephropathy who had surgery hadurothelial carcinomaIARCAristolochic acid and plantscontaining it: Group 1, carcinogenicto humansFDAImport Alert 54-10: detention ofsupplements containing aristolochicacidArtemisinin and aristolochic acid historiesA lead that became a medicine: artemisininTextGe Hong's Handbook of Prescriptions forEmergencies: qinghao steeped in cold water, juicedrunk1969Over 2,000 prescriptions gathered, 640 shortlistedOct 4, 1971Sample 191, neutral ether extract made at lowtemperature: 100% effective in rodent malaria1972First patients, Aug to Oct; artemisinin isolated inNovember1986Artemisinin New Drug Certificate, China2015Nobel Prize in Physiology or Medicine, one half toTu YouyouA traditional ingredient that caused harm:aristolochic acidBelgiumAristolochia fangchi replaced Stephania tetrandrain Belgian slimming pillsNEJM, 200018 of 39 patients with end-stage nephropathy whohad surgery had urothelial carcinomaIARCAristolochic acid and plants containing it: Group 1,carcinogenic to humansFDAImport Alert 54-10: detention of supplementscontaining aristolochic acid
Tu Youyou, Nobel Lecture, December 7, 2015, and nobelprize.org 2015 prize summary; Nortier JL et al., N Engl J Med 2000;342:1686–1692; IARC Monographs list of classifications; FDA Import Alert 54-10 (published December 10, 2020).
What controlled studies found after long traditional use
BotanicalFindingLessonSource
Qinghao (Artemisia annua)A cold-water preparation in Ge Hong's text led to low-temperature extraction; sample 191 was 100% effective in rodent malaria on October 4, 1971; artemisinin was isolated in November 1972The text pointed to a method; isolation and trials made the medicineTu, Nobel Lecture 2015
St John's wort (Hypericum perforatum)29 trials, 5,489 patients with major depression: extracts “superior to placebo, similarly effective as standard antidepressants, and had fewer side effects”; products “vary to a great extent”An effect can be real and still not transfer from one product to anotherLinde et al., Cochrane 2008, CD000448.pub3
St John's wort, interactionAn extract supplying 41 mg hyperforin a day for 14 days cut oral midazolam exposure (AUC0–12 h) by 79.4% in one of six parallel groups of a 42-man studyEffective herbs can lower exposure to other medicinesMueller et al., Eur J Clin Pharmacol 2006
Aristolochia speciesSubstituted into Belgian slimming pills; 18 of 39 patients with end-stage nephropathy who had surgery had urothelial carcinomaIdentity errors and slow harms are invisible to traditionNortier et al., NEJM 2000; IARC Group 1
Green tea catechins (EGCG)800 mg EGCG a day or more as a food supplement significantly raised serum transaminases; EFSA was “unable to identify a safe dose”A concentrated extract is not the traditional infusionEFSA ANS Panel, EFSA Journal 2018;16(4):5239
EphedraFDA declared supplements containing ephedrine alkaloids adulterated as presenting an unreasonable risk (final rule February 11, 2004)Traditional use did not predict harm at supplement doses69 FR 6788
Herbal and dietary supplements, all130 of 839 drug-induced liver injury cases (15.5%) in the DILIN registry; share rose from 7% to 20% over the studyCaveat: a referral-center cohort; the authors did not conclude a national riseNavarro et al., Hepatology 2014;60:1399–1408

All sources opened or confirmed October 28, 2026; full citations in the reference list.

Comparison

Middle paths in other systems

Several systems license a traditional-use product for minor, self-care indications on bibliographic evidence of long use plus quality and safety data, without efficacy trials. None of the EU, Canadian or Australian routes extends to serious disease. The United States has no such middle tier: a botanical either carries a structure/function or health claim, or becomes a drug. WHO's Traditional Medicine Strategy 2025–2034 was adopted by the 78th World Health Assembly on May 27, 2025; WHO reports that 170 Member States report the use of traditional medicine.

Five systems have a route grounded in traditional use; the United States does notStatute and regulation Simplified
Six systems compared: whether a traditional-use route exists, whether it is reviewed before sale, and whether it allows serious-disease claimsRoute based on traditional useReviewed before saleSerious disease on that routeUnited StatesNoneStructure/function: noNoEuropean UnionRegistration, 30 years of use (15 in EU)Yes, registrationNo: self-care indicationsCanadaProduct license (NPN)Yes, licenseNo: modern evidence neededAustraliaListed medicine (AUST L)Indications not evaluated at listingNo: health maintenance, minorconditionsChinaClassical-prescription registrationYes, simplified; no clinical trialsNot assessed hereIndiaAyurveda, Siddha, Unani drugs byclassical formulaeLicensing not assessed hereDrug definition covers treatment ofdiseaseSix systems compared on traditional-use routesUnited StatesRoute: None · Review: Structure/function: no ·Serious disease: NoEuropean UnionRoute: Registration, 30 years of use (15 in EU) ·Review: Yes, registration · Serious disease: No:self-care indicationsCanadaRoute: Product license (NPN) · Review: Yes,license · Serious disease: No: modern evidenceneededAustraliaRoute: Listed medicine (AUST L) · Review:Indications not evaluated at listing · Seriousdisease: No: health maintenance, minor conditionsChinaRoute: Classical-prescription registration · Review:Yes, simplified; no clinical trials · Serious disease:Not assessed hereIndiaRoute: Ayurveda, Siddha, Unani drugs by classicalformulae · Review: Licensing not assessed here ·Serious disease: Drug definition covers treatmentof disease
Details are in the table below. “Not assessed here” means this page did not verify the point from a primary source.
Traditional-use routes compared
SystemRouteEvidence of useClaim scopeSource
European UnionSimplified registration of a traditional herbal medicinal productMedicinal use for at least 30 years before application, including at least 15 years in the Community; data must show the product is not harmful and its effects plausibleIndications appropriate without medical supervision; oral, external or inhaled; fixed strength and posology; label says the use is “exclusively based upon long-standing use”Directive 2004/24/EC, Arts 16a, 16c, 16g
CanadaNatural health product license (NPN) before sale; site license to make or import“Two generations of safe traditional use”; one recognized system per formulation (TCM, Ayurveda, First Nations ethnomedicine, traditional herbal medicine)Wording names the system (“traditionally used in Ayurvedic medicine”); serious-disease claims need modern evidenceNatural Health Products Regulations; Health Canada traditional-medicines pathway (modified July 6, 2022)
AustraliaListed medicine (AUST L) with permitted low-risk ingredients, made under GMPSponsor certifies it holds evidence; indications “not evaluated by the TGA at the time a medicine is listed”Health maintenance and enhancement, and certain non-serious, self-limiting conditionsTGA, Listed complementary medicines (May 4, 2018)
ChinaSimplified registration of compound preparations from ancient classical prescriptionsReview combines TCM theory, human-use experience and clinical trials; classical-prescription preparations need no non-clinical efficacy research or clinical trialsRegistered as medicines; scope not assessed hereTCM Law, adopted December 25, 2016, in force July 1, 2017; Special Regulations on TCM Registration, in force July 1, 2023, Arts 6, 13, 48
IndiaAyurvedic, Siddha and Unani drugs under the Drugs and Cosmetics Act, 1940; Ministry of AyushMade “exclusively in accordance with the formulae described in” authoritative books listed in the First ScheduleDefined as drugs for diagnosis, treatment, mitigation or prevention of disease; licensing detail not assessed hereCDSCO, Traditional Drugs page; Drugs and Cosmetics Rules, 1945, Part XVI
United StatesNone based on traditional useNot a recognized basis for a claimStructure/function or health claims; disease treatment only as an approved drug21 USC 321(g)(1), 343(r)

Sources: EUR-Lex 32004L0024; Health Canada, Pathway for Licensing Natural Health Products used as Traditional Medicines; TGA; National Health Commission of China, December 26, 2016; NMPA Special Regulations (English text in NMPA newsletter, 2024); CDSCO; WHO document A78/14 and WHO news, November 14, 2025. Traditional use elsewhere does not by itself authorize sale in the EU or the United States.

Remedies

What can legitimately be done

The gap cannot be closed by wording; it is closed by evidence on a defined product. The claim goal decides the route, and for a disease-treatment goal the order of events matters before any study is public. FDA's 2016 guidance gives one concrete advantage to traditional botanicals already sold lawfully: early clinical studies may need less chemistry detail and no new nonclinical testing when prior human use is similar to the proposed use.

The claim goal selects the route; for a drug, first lawful use is decided before anything is publicProposed approach Schematic
Decision drawing: the claim goal selects the route, supplement, health claim petition, botanical drug or traditional-use route abroad; for a drug, the first-lawful-use decision comes firstA botanical with a history of traditional useWhich statement should the label eventually carry?Support of normal structure orfunctionSupplementIdentified, standardized extract;registered and published trials assubstantiation; 30-day notice anddisclaimerReduced risk of a diseaseHealth claim petitionAuthorized claim needs significantscientific agreement; a qualifiedclaim rests on less and carriesqualifying wordsTreatment of a diseaseBotanical drugDecide first lawful use, then an IND,often in a separate entity; priorhuman use may reduce earlyrequirementsSale outside the USTraditional-use route abroadEU registration, Canadian license orAustralian listing, each on its ownevidence rulesBefore any IND is public: is the ingredient already lawfully sold as asupplement or food? If not, a public drug investigation closes the supplementchannel.Which legitimate route fits which claim goalA botanical with a history of traditional useWhich statement should the label eventually carry?If the goal is: Support of normal structure or functionSupplementIdentified, standardized extract; registered andpublished trials as substantiation; 30-day noticeand disclaimerIf the goal is: Reduced risk of a diseaseHealth claim petitionAuthorized claim needs significant scientificagreement; a qualified claim rests on less andcarries qualifying wordsIf the goal is: Treatment of a diseaseBotanical drugDecide first lawful use, then an IND, often in aseparate entity; prior human use may reduceearly requirementsIf the goal is: Sale outside the USTraditional-use route abroadEU registration, Canadian license or Australianlisting, each on its own evidence rulesFor a drug: settle first lawful use before any IND ispublic.
Routes from 21 USC 321(ff)(3)(B) and 343(r); 21 CFR 101.14 and 101.93; FDA Botanical Drug Development guidance (2016), Sections V.B, V.C and V.E; Directive 2004/24/EC; Health Canada; TGA.
Legitimate remedies and what EUTECNIQ would do Proposed
RemedyWhat it givesWhat it requiresEUTECNIQ would
Standardized, identified extractA defined product that a trial result can attach toIdentity testing of every dietary ingredient (21 CFR 111.75(a)(1)(i)); marker and fingerprint specificationsWrite specifications before any study starts
Registered, published trials on that productSubstantiation for structure/function statements; the evidence base for any later petitionProspective registration, IRB review, the finished product as testedDesign and oversee trials run by qualified partners
Health claim or qualified health claim petitionA disease-risk-reduction claim usable by any product meeting the conditionsSignificant scientific agreement, or for a qualified claim weaker evidence with qualifying languageAssess whether the evidence supports a petition
Botanical IND, often in a separate entityA path to a treatment claim, plus statutory exclusivity on approval2016 guidance: raw-material, CMC and bioassay control across batches; adequate clinical evidencePrepare the CMC and consistency package; sponsorship by a partner or spin-out
Early first-lawful-use decisionKeeps or deliberately closes the supplement channelA decision before any drug investigation is public (21 USC 321(ff)(3)(B))Flag the decision at the first gate of each program, with counsel
Traditional-use license abroadA labeled traditional indication in the EU, Canada or AustraliaEach system's evidence rules, quality data and a local applicantCompile bibliographic and quality dossiers for partners

EUTECNIQ column: proposal only; no program, study, petition or IND exists. Route requirements as cited in the sections above.

Safety and consistency

Safe and consistent botanicals

Each failure listed under traditional use maps to a control that exists today. The methods are covered in depth on the linked pages; this table shows where each one enters.

Controls that answer the failures of traditional evidence
Failure modeControlRule or methodRead more
Wrong species or adulterantIdentity test before use21 CFR 111.75(a)(1)(i); orthogonal methods, since a single method can misleadPlant identity
Variable compositionStandardization and batch consistencyMarker and fingerprint specifications; for drugs, FDA's totality-of-evidence approach (2016)Analytical technologies
Dose not known to be safeDose from a NOAEL and a human-equivalent doseHED = animal dose × (animal weight ÷ human weight)0.33; for the rat, divide the mg/kg dose by 6.2 (FDA 2005, Table 1)Risk assessment
Interactions with medicinesClinical interaction studies on the productProbe-substrate studies such as the St John's wort–midazolam study aboveADME and PBPK
Slow harms (cancer, kidney)Repeated-dose and long-term toxicity studiesOECD test guidelines run under GLP (21 CFR Part 58)Toxicology programs
Harm seen only after launchPost-market adverse-event reportingSerious adverse events reported to FDA within 15 business days (21 USC 379aa-1)Lessons learned

Sources: eCFR 21 CFR 111.75 and Part 58; FDA, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (July 2005), Table 1 and Table 3 footnote; 21 USC 379aa-1. The HED arithmetic is a teaching example, not a dosing method.

Proposed role

Where EUTECNIQ would work

EUTECNIQ would build the product-specific evidence the gap demands: identity and standardization first, then registered trials through partners, then a deliberate route decision for each ingredient, including when a drug program belongs in a separate entity. It would make no disease claims for supplements. Proposed

Related pages: Course 10, Supplements and disease claims · Proposed pipeline · Clinical research · International market access · NDIN strategy and dossiers · History of botanical medicine

Planning evidence for a traditional botanical?

Start with identity, a defined product and the route decision. EUTECNIQ is in formation and welcomes early conversations.

Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.

Read the full notice

The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]